Cepheid Gets FDA OK for Thrombosis Test | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market Thursday that the US Food and Drug Administration has cleared for marketing its Xpert HemosIL FII & FV test.

The test detects Factor II and V Leiden genetic variations associated with thrombophilia. It runs on the firm's GeneXpert system and provides results in just over 30 minutes. The test will be distributed exclusively by Instrumentation Laboratory.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.